Skip to content

Nasdaq · CIK 0001710340

ETON Eton Pharmaceuticals, Inc.

Insider trading from SEC Form 4. Last filing 6 d ago. Close $55.21 on Oct 9, 2026, +285% from the 52-week low and -14% from the high.

Last 90 days

Net insider value
-$229k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$229k by 1 insider
Insiders on file
9
with a Form 4 at this company

Price and insider trades, last year

ETONOct 9, 2026 · close 55.21

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Eton Pharmaceuticals, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
13WeakDavid Krempa
Chief Business Officer
sell
$229k
4,166 shares
-9%+282% from low-15% from high
47ModerateJames R. Gruber
Chief Financial Officer
sell
$674k
41,713 shares
-17%+238% from low-20% from high
41ModerateDavid Krempa
Chief Business Officer
sell
$504k
34,000 shares
-5%+203% from low-28% from high
27WeakOpaleye Management Inc.
owner
buy
$125k
7,930 shares
+0%+228% from low-22% from high
58ModerateSean Brynjelsen
President & CEO
sell
$3.6M
210,000 shares
-7%+261% from low-15% from high
11WeakOpaleye Management Inc.
owner
buy
$80k
10,000 shares
+0%-

Transactions

The last 38 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Oct 2, 2026David Krempa
Chief Business Officer
MOption exercise
Common Stock
+10,522--47,5476 d ago
Oct 6, 2026David Krempa
Chief Business Officer
SOpen-market sale
Common Stock
-4,166$55.07$229k43,3816 d ago
Oct 2, 2026David Krempa
Chief Business Officer
MOption exercise
Restricted Stock Unitsderivative
-10,522$0.00$021,0446 d ago
Dec 12, 2025Sean Brynjelsen
President & CEO
FTax withholding
Common Stock
-6,732$16.83$113k2,894,281Dec 12, 2025
Dec 12, 2025Ipek Erdogan-Trinkaus
Chief Commercial Officer
FTax withholding
Common Stock
-85$16.90$1,4372,403Dec 12, 2025
Dec 12, 2025James R. Gruber
Chief Financial Officer
FTax withholding
Common Stock
-4,542$16.99$77k215,713Dec 12, 2025
Dec 12, 2025David Krempa
Chief Business Officer
FTax withholding
Common Stock
-6,264$17.00$106k632,180Dec 12, 2025
Dec 11, 2025James R. Gruber
Chief Financial Officer
AGrant or award
Restricted Stock Unitsderivative
+5,502$0.00$0210,255Dec 12, 2025
Dec 11, 2025David Krempa
Chief Business Officer
AGrant or award
Restricted Stock Unitsderivative
+5,300$0.00$0638,468Dec 12, 2025
Aug 19, 2025James R. Gruber
Chief Financial Officer
SOpen-market sale
Common Stock
-39,082$16.16$632k205,299Aug 20, 2025
Aug 20, 2025James R. Gruber
Chief Financial Officer
SOpen-market sale
Common Stock
-2,631$16.02$42k204,753Aug 20, 2025
Jun 12, 2025David Krempa
Chief Business Officer
SOpen-market sale
Common Stock
-16,977$14.92$253k629,669Jun 16, 2025
Jun 13, 2025David Krempa
Chief Business Officer
SOpen-market sale
Common Stock
-6,800$14.77$100k622,869Jun 16, 2025
Jun 16, 2025David Krempa
Chief Business Officer
SOpen-market sale
Common Stock
-10,223$14.73$151k612,646Jun 16, 2025
Jun 10, 2025Opaleye Management Inc.
owner
POpen-market purchase
Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P.
+5,000$15.82$79k2,770,000Jun 12, 2025
Jun 10, 2025Opaleye Management Inc.
owner
POpen-market purchase
Common Stock, par value $0.001 per shareindirect: Managed Account
+2,930$15.82$46k85,000Jun 12, 2025
Jun 3, 2025Sean Brynjelsen
President & CEO
SOpen-market sale
Common Stock
-60,945$17.38$1.1M3,022,568Jun 5, 2025
Jun 3, 2025Sean Brynjelsen
President & CEO
SOpen-market sale
Common Stock
-8,655$18.38$159k3,013,913Jun 5, 2025
Jun 3, 2025Sean Brynjelsen
President & CEO
SOpen-market sale
Common Stock
-400$19.02$7,6083,013,513Jun 5, 2025
Jun 4, 2025Sean Brynjelsen
President & CEO
SOpen-market sale
Common Stock
-70,000$17.00$1.2M2,943,513Jun 5, 2025
Jun 5, 2025Sean Brynjelsen
President & CEO
SOpen-market sale
Common Stock
-70,000$16.81$1.2M2,873,513Jun 5, 2025
Jan 3, 2025Jennifer McKie Adams
director
AGrant or award
Employee Stock Option (Right to Buy)derivative
+25,000$0.00$025,000Jan 6, 2025
Jan 3, 2025Sean Brynjelsen
President & CEO
AGrant or award
Employee Stock Option (Right to Buy)derivative
+107,469$0.00$0107,469Jan 6, 2025
Jan 3, 2025Charles J Casamento
director
AGrant or award
Employee Stock Option (Right to Buy)derivative
+25,000$0.00$025,000Jan 6, 2025
Jan 3, 2025James R. Gruber
Chief Financial Officer
AGrant or award
Employee Stock Option (Right to Buy)derivative
+38,621$0.00$038,621Jan 6, 2025
Jan 3, 2025Norbert G Riedel
director
MOption exercise
Common Stock
+27,400$3.58$98k87,145Jan 6, 2025
Jan 3, 2025David Krempa
Chief Business Officer
AGrant or award
Employee Stock Option (Right to Buy)derivative
+38,621$0.00$038,621Jan 6, 2025
Jan 3, 2025Paul Maier V
director
AGrant or award
Employee Stock Option (Right to Buy)derivative
+25,000$0.00$025,000Jan 6, 2025
Jan 3, 2025Norbert G Riedel
director
AGrant or award
Employee Stock Option (Right to Buy)derivative
+25,000$0.00$025,000Jan 6, 2025
Jan 3, 2025David Krempa
Chief Business Officer
AGrant or award
Restricted Stock Unitsderivative
+25,876$0.00$025,876Jan 6, 2025
Jan 3, 2025Norbert G Riedel
director
MOption exercise
Common Stock
+50,000$3.78$189k137,145Jan 6, 2025
Jan 3, 2025James R. Gruber
Chief Financial Officer
AGrant or award
Restricted Stock Unitsderivative
+25,876$0.00$025,876Jan 6, 2025
Jan 3, 2025Sean Brynjelsen
President & CEO
AGrant or award
Restricted Stock Unitsderivative
+72,004$0.00$072,004Jan 6, 2025
Jan 3, 2025Norbert G Riedel
director
MOption exercise
Common Stock
+25,000$3.47$87k162,145Jan 6, 2025
Jan 3, 2025Norbert G Riedel
director
MOption exercise
Employee Stock Option (Right to Buy)derivative
-27,400$0.00$00Jan 6, 2025
Jan 3, 2025Norbert G Riedel
director
MOption exercise
Employee Stock Option (Right to Buy)derivative
-50,000$0.00$00Jan 6, 2025
Jan 3, 2025Norbert G Riedel
director
MOption exercise
Employee Stock Option (Right to Buy)derivative
-25,000$0.00$00Jan 6, 2025
Oct 23, 2024Opaleye Management Inc.
owner
POpen-market purchase
Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P.
+10,000$7.98$80k2,770,000Oct 25, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

ETON insider trading: Eton Pharmaceuticals, Inc. | InsiderTell